Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Association between Perioperative Blood Transfusion and Oncologic Outcomes after Curative Surgery for Renal Cell Carcinoma.

Park YH, Kim YJ, Kang SH, Kim HH, Byun SS, Lee JY, Hong SH.

J Cancer. 2016 May 12;7(8):965-72. doi: 10.7150/jca.15073. eCollection 2016.

2.

Renal Cancer Stem Cells: Characterization and Targeted Therapies.

Peired AJ, Sisti A, Romagnani P.

Stem Cells Int. 2016;2016:8342625. doi: 10.1155/2016/8342625. Epub 2016 May 15. Review.

3.

Diagnostic accuracy of pre-operative imaging findings in presumed clinical T1a renal cell carcinomas.

Nakashima K, Kitagawa Y, Izumi K, Mizokami A, Gabata T, Namiki M.

Oncol Lett. 2016 May;11(5):3189-3193. Epub 2016 Mar 16.

4.

Coexistence of Essential Thrombocythemia, Iron-Refractory Iron Deficiency Anemia and Renal Cell Carcinoma.

Namdaroğlu S, Tekgündüz E, Altuntaş F.

Hematol Rep. 2016 Mar 18;8(1):6235. doi: 10.4081/hr.2016.6235. eCollection 2016 Mar 17.

5.

Prognostic value of preoperative inflammatory response biomarkers in patients with sarcomatoid renal cell carcinoma and the establishment of a nomogram.

Gu L, Ma X, Li H, Chen L, Xie Y, Zhao C, Luo G, Zhang X.

Sci Rep. 2016 Mar 31;6:23846. doi: 10.1038/srep23846.

6.

Renal cell carcinoma: A nomogram for the CT imaging-inclusive prediction of indolent, non-clear cell renal cortical tumours.

Karlo CA, Kou L, Di Paolo PL, Kattan MW, Motzer RJ, Russo P, Tickoo SK, Akin O, Hricak H.

Eur J Cancer. 2016 May;59:57-64. doi: 10.1016/j.ejca.2016.02.012. Epub 2016 Mar 24.

PMID:
27016623
7.

Evaluation of oxidative stress status and antioxidant capacity in patients with renal cell carcinoma.

Aldemir M, Karaguzel E, Okulu E, Gudeloglu A, Ener K, Ozayar A, Erel O.

Cent European J Urol. 2015;68(4):415-20. doi: 10.5173/ceju.2015.656. Epub 2015 Nov 23.

8.

Clinicohistological characteristics of renal cell carcinoma in children: A multicentre study.

Kim JH, Seo SI, Song C, Chung J, Kwak C, Hong SH.

Can Urol Assoc J. 2015 Sep-Oct;9(9-10):E705-8. doi: 10.5489/cuaj.2855. Epub 2015 Oct 13.

9.

Recurrence pattern in patients with locally advanced renal cell carcinoma: The implications of clinicopathological variables.

Sameh WM, Hashad MM, Eid AA, Abou Yousif TA, Atta MA.

Arab J Urol. 2012 Jun;10(2):131-7. doi: 10.1016/j.aju.2011.12.007. Epub 2012 Feb 18.

10.

Collecting (Bellini) duct carcinoma: A clinical study of a rare tumour and review of the literature.

Ciszewski S, Jakimów A, Smolska-Ciszewska B.

Can Urol Assoc J. 2015 Sep-Oct;9(9-10):E589-93. doi: 10.5489/cuaj.2932. Epub 2015 Sep 9.

11.

Impact of preoperative radiological and postoperative pathological findings on survival of patients after radical nephrectomy performed with the indication of renal cell carcinoma.

Şimşek A, Küçüktopcu O, Akbulut F, Özgör F, Küçüktopcu E, Savun M, Berberoğlu Y, Gürbüz G.

Turk J Urol. 2015 Mar;41(1):1-6. doi: 10.5152/tud.2015.78800.

12.

Histologic subtype impacts cancer-specific survival in patients with sarcomatoid-variant renal cell carcinoma treated surgically.

Nguyen DP, Vilaseca A, Vertosick EA, Corradi RB, Touijer KA, Benfante NE, Sjoberg DD, Russo P.

World J Urol. 2016 Apr;34(4):539-44. doi: 10.1007/s00345-015-1644-y. Epub 2015 Jul 28.

PMID:
26215750
13.

Diagnostic potential of multidetector computed tomography for characterizing small renal masses.

Mancini ME, Albergo A, Moschetta M, Angelelli M, Scardapane A, Angelelli G.

ScientificWorldJournal. 2015;2015:476750. doi: 10.1155/2015/476750. Epub 2015 Apr 9.

14.

Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.

Sankin A, Hakimi AA, Hsieh JJ, Molina AM.

Front Oncol. 2015 Apr 8;5:67. doi: 10.3389/fonc.2015.00067. eCollection 2015. Review.

15.

Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma?

Lee SH, Son HS, Cho S, Kim SJ, Yoo DS, Kang SH, Park SY, Park J, Chang SG, Jeon SH.

Cancer Res Treat. 2015 Jul;47(3):489-94. doi: 10.4143/crt.2014.013. Epub 2014 Nov 17.

16.

VEGF/VEGFR2 and PDGF-B/PDGFR-β expression in non-metastatic renal cell carcinoma: a retrospective study in 1,091 consecutive patients.

Song SH, Jeong IG, You D, Hong JH, Hong B, Song C, Jung WY, Cho YM, Ahn H, Kim CS.

Int J Clin Exp Pathol. 2014 Oct 15;7(11):7681-9. eCollection 2014.

17.

The incidence of renal cancer in Polish National Cancer Registry: is there any epidemiological data we can rely on?

Wojcieszak PZ, Poletajew S, Rutkowski D, Radziszewski P.

Cent European J Urol. 2014;67(3):253-6. doi: 10.5173/ceju.2014.03.art8. Epub 2014 Aug 18.

18.

Let-7d suppresses growth, metastasis, and tumor macrophage infiltration in renal cell carcinoma by targeting COL3A1 and CCL7.

Su B, Zhao W, Shi B, Zhang Z, Yu X, Xie F, Guo Z, Zhang X, Liu J, Shen Q, Wang J, Li X, Zhang Z, Zhou L.

Mol Cancer. 2014 Sep 6;13:206. doi: 10.1186/1476-4598-13-206.

19.

CT perfusion in the characterisation of renal lesions: an added value to multiphasic CT.

Mazzei FG, Mazzei MA, Cioffi Squitieri N, Pozzessere C, Righi L, Cirigliano A, Guerrini S, D'Elia D, Ambrosio MR, Barone A, del Vecchio MT, Volterrani L.

Biomed Res Int. 2014;2014:135013. doi: 10.1155/2014/135013. Epub 2014 Aug 13.

20.

Specific genomic aberrations predict survival, but low mutation rate in cancer hot spots, in clear cell renal cell carcinoma.

Köhn L, Svenson U, Ljungberg B, Roos G.

Appl Immunohistochem Mol Morphol. 2015 May-Jun;23(5):334-42. doi: 10.1097/PAI.0000000000000087.

Items per page

Supplemental Content

Write to the Help Desk